repostive logoCambridge (UK) tech start-up, Repositive, has successfully concluded the pilot phase of its data-sharing platform for PDX cancer models and is now extending the scope of the platform to include a wider range of translational cancer models. The platform enables oncology researchers to identify the particular cancer models that optimally represent specific cancer types and targeted patient sub-populations. It is the only one of its kind, being both globally accessible (not restricted to academics only or individual vendors) and searchable down to specific genomic characteristics.

Early adopter of the Repositive PDX Platform, Philippe Michon, Head of Business Development at XenTech, explains: “The Repositive platform answers one great challenge in preclinical oncology; by allowing scientists to search and access PDX model collections from around the world, it gives the ability to precisely pinpoint in a matter of a few clicks the exact PDX model sought”.

Building on the success of the past 12 months of piloting the PDX Platform and based on feedback from the platform’s early adopters, the scope of the platform has now been extended: the beta version operates beyond PDX to incorporate a wider range of cancer models into the searchable platform. The new Cancer Models Platform Version 1 will provide a single portal for researchers to source a broad range of translational cancer models and related services worldwide. The Repositive team will be demonstrating this new Cancer Models Platform at the American Association for Cancer Research (AACR) Annual Meeting, Chicago, in April.

Fiona Nielsen

Fiona Nielsen, Founder & CEO, Repostive

Fiona Nielsen, Founder and CEO of Repositive, said: “We will be demonstrating the beta version of the new Cancer Models Platform on our stand at AACR and welcome feedback from as many people involved in pre-clinical cancer research as possible. We would like to see researchers and representatives from both cancer model vendors and pharmaceutical companies, whether current collaborators or new contacts, to test the platform and feedback on its usability. We want to know what more we can do to support better and faster research of cancer cures!

Repositive will be hosting a networking event during ACCR on 17th April, from 6:30 pm to 9.00 pm. 

“The event will include a panel discussion on the strengths and limitations of current popular model types, the opportunities and challenges of the newer 3D in vitro formats, and the relative merits of syngeneic vs humanized mice for immuno-oncology projects. We hope to meet many more people who share our passion for translational oncology at the event, which takes place at the Marriot Marquis, 2121 S Prairie Ave, Chicago.”

 

More on these topics